11 – 20 of 22
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2002
-
Mark
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Tumour microvessel density as predictor of chemotherapy response in breast cancer patients
(
- Contribution to journal › Article
-
Mark
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Physical performance, toxicity, and quality of life as assessed by the physician and the patient
(
- Contribution to journal › Article
- 2001
-
Mark
Timing of quality of life (QoL) assessments as a source of error in oncological trials
(
- Contribution to journal › Article
- 2000
-
Mark
Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol
(
- Contribution to journal › Article
-
Mark
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group
(
- Contribution to journal › Article
-
Mark
Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer : a randomised trial
(
- Contribution to journal › Article
- 1999
-
Mark
Chemotherapy in Ewing's sarcoma. The Scandinavian Sarcoma Group experience
(
- Contribution to journal › Article